BeAT1D: Benign Autoimmunity and Type 1 Diabetes

Launched by INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, FRANCE · Nov 18, 2021

Keywords

ClinConnect Summary

The BeAT1D clinical trial is studying how certain immune cells contribute to the development of type 1 diabetes, a condition that affects how your body manages blood sugar. This research involves collecting samples from various participants to better understand the role of specific immune cells in this type of diabetes. The goal is to learn more about these immune responses, which could help in creating better treatments or preventative measures in the future.

To be eligible for this study, participants should have type 1 diabetes, which is usually diagnosed when someone has high blood sugar and needs insulin treatment shortly after symptoms appear. The study also includes individuals without diabetes, as well as those with other types of diabetes or autoimmune conditions. Participants can expect to provide biological samples and contribute to important research that could improve our understanding of type 1 diabetes. It's important to note that certain people, like those who are pregnant or have specific infections, cannot participate. Overall, this study aims to gather valuable information that could lead to advancements in diabetes care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Type 1 diabetes: type 1 diabetes, as defined by hyperglycemia and long-term insulin therapy started within 6 months from clinical onset; and/or the presence of at least one anti-islet auto-antibody.
• • 2. Other forms of diabetes or autoimmune endocrinopathy: other forms of diabetes (e.g. type 2, ketosis-prone, familial, secondary, immunotherapy-induced diabetes); and/or other autoimmune endocrinopathies, isolated or multiple.
• • 3. No diabetes: absence of diabetes or impaired glucose tolerance; absence of tumor, infectious or immune pathologies, or other conditions related to autoimmune or metabolic alterations that may bias the variables under study.
• • 4. Lymphadenectomy planned in the frame of an abdominal surgery: pancreatic lymphadenectomy planned at the occasion of an abdominal surgery for the treatment of an underlying condition.
• Exclusion Criteria:
• • For all participants: ongoing pregnancy; known HIV/HCV infection; absence of social security coverage; placement under judicial protection; absence of signature of the informed study consent.